<DOC>
	<DOCNO>NCT00948467</DOCNO>
	<brief_summary>The purpose study evaluate safety , pharmacokinetics , pharmacodynamics maximum tolerate dose TAK-733 patient advance , nonhematologic tumor . The expansion stage study evaluate evidence antitumor activity TAK-733 patient advance metastatic melanoma .</brief_summary>
	<brief_title>Study TAK-733 Adult Patients With Advanced Nonhematologic Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Each patient must meet follow inclusion criterion enrol study : 18 year old . Have one follow diagnosis : nonhematologic malignancy standard , curative , lifeprolonging treatment exist longer effective ; OR stage 3 stage 4 unresectable melanoma priorly treat either MEK BRAF inhibitor therapy . Melanoma patient V600E BRAF mutation status tumor document , available , tumor tissue must provide confirmatory genotyping central laboratory . Have radiographically clinically evaluable tumor . Have suitable venous access conduct blood sampling . Provide voluntary write consent , withdrawn patient time . Female patient : postmenopausal least 1 year screening ; OR surgically sterile ; OR childbearing potential agree practice two effective method birth control time sign informed consent form 30 day last dose study drug , agree completely abstain heterosexual intercourse . Male patient , even surgically sterilize , must agree practice effective barrier contraception entire study treatment period 30 day last dose study drug ; OR agree completely abstain heterosexual intercourse . Patients meet follow exclusion criterion enrol study : Female patient lactate positive serum pregnancy test Screening period . Antineoplastic therapy radiotherapy within 21 day ; nitrosoureas mitomycin C within 42 day Prior biologic immunotherapy â‰¤ 4 week prior enrollment . Grade 2 great unresolved toxicity ( except alopecia ) previous anticancer therapy . Major surgery within 14 day first dose study drug . An active infection require systemic therapy ; severe infection . Symptomatic brain metastasis . Inability meet specific laboratory test standard Screening period specify study protocol . Human Immunodeficiency ( HIV ) positive . Hepatitis B surface antigen positive active hepatitis C infection . Serious medical psychiatric illness likely interfere study . Uncontrolled cardiovascular condition . Abnormalities 12lead ECG perform within 28 day start study drug consider clinically significant rate correct QT interval &gt; 470 millisecond . Melanoma patient exclude diagnosis treatment another malignancy within 2 year first dose study drug , previously diagnose another malignancy evidence residual disease . Treatment investigational product within 28 day first dose study drug . A history ongoing newly diagnose eye abnormality , retinal corneal pathology . Abnormal leave ventricular ejection fraction ( LVEF ) . Receiving therapeutic anticoagulation Treatment follow strong CYP3A inhibitor inducer within 14 day first dose study drug : ketoconazole , itraconazole , voriconazole , posaconazole , clarithromycin , telithromycin , nefazodone , rifampin , rifapentine , rifabutin .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Advanced nonhematologic malignancy</keyword>
	<keyword>Advanced metastatic melanoma</keyword>
	<keyword>BRAF gene</keyword>
</DOC>